|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 0.8480 SEK | +36.77% |
|
-58.63% | -56.95% |
| 11-13 | Irlab narrows operating loss | FW |
| 11-13 | IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| Market Cap | 126M 12.53M 11.36M 10.5M 9.48M 17.88M 1.18B 18.49M 50.01M 630M 47.07M 46.02M 2.02B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 126M 12.53M 11.36M 10.5M 9.48M 17.88M 1.18B 18.49M 50.01M 630M 47.07M 46.02M 2.02B | EV / Sales 2026 * |
1.25x | EV / Sales 2027 * | 0.88x |
| Free-Float |
83.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| IRLAB A | Delayed | |
OTC Markets
| IRLAF | Delayed | |
|
Deutsche Boerse AG
| 6IRA | Delayed |
| 1 day | +36.77% | ||
| 1 week | -58.63% | ||
| Current month | -59.43% | ||
| 1 month | -55.08% | ||
| 3 months | -48.54% | ||
| 6 months | -30.61% | ||
| Current year | -56.95% |
| 1 week | 0.56 |  | 2.28 |
| 1 month | 0.56 | | 2.28 |
| Current year | 0.56 | | 2.28 |
| 1 year | 0.56 | | 2.44 |
| 3 years | 0.56 | | 20.2 |
| 5 years | 0.56 | | 51.5 |
| 10 years | 0.56 | | 110 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2024-07-31 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 2012-12-31 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 2015-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 2015-12-31 |
| Chairman | 73 | 2020-05-06 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 2022-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/1/26 | Buy | Chairman | 31,000 | 38.8588% | ||
| 7/1/26 | Buy | Chief Technology Officer | 4,016,742 | - | ||
| 7/1/26 | Buy | Chief Executive Officer | 183,858 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +36.77% | -58.63% | -63.45% | -86.95% | 12.52M | |
| +1.26% | +6.61% | +40.79% | +136.32% | 1,286B | |
| +0.79% | +3.45% | +45.84% | +93.52% | 688B | |
| +0.20% | +1.28% | +26.97% | +113.70% | 521B | |
| -0.44% | +3.69% | +41.45% | +68.91% | 386B | |
| +0.55% | +0.70% | +59.02% | +44.62% | 364B | |
| -0.12% | +0.74% | +28.39% | +58.54% | 302B | |
| +0.37% | +0.37% | +3.33% | +37.27% | 287B | |
| -0.30% | +1.14% | +38.29% | +72.46% | 252B | |
| +0.08% | +0.71% | +34.44% | +124.95% | 208B | |
| Average | +3.92% | -3.99% | +25.51% | +66.33% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.70% | +96.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 101M 10.06M 9.12M 8.42M 7.61M 14.35M 949M 14.84M 40.13M 506M 37.78M 36.93M 1.62B | 143M 14.23M 12.9M 11.92M 10.76M 20.3M 1.34B 21M 56.78M 716M 53.46M 52.26M 2.29B |
| Net income | -36.1M -3.59M -3.25M -3M -2.71M -5.12M -338M -5.29M -14.32M -180M -13.48M -13.17M -577M | 34.6M 3.44M 3.12M 2.88M 2.6M 4.91M 324M 5.07M 13.72M 173M 12.92M 12.63M 553M |
| Net Debt | - | - |
Employees
31
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | SEK 0.8480 | +36.77% | 45,161,383 |
| 26-11-12 | SEK 0.6200 | -70.96% | 51,047,606 |
| 26-11-11 | SEK 2.135 | -4.90% | 1,774,914 |
| 26-11-10 | SEK 2.245 | +6.90% | 2,778,273 |
| 26-11-09 | SEK 2.100 | +2.44% | 2,038,072 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IRLAB A Stock
Select your edition
All financial news and data tailored to specific country editions
